PTN logo

PALATIN TECHNOLOGIES INC

PTNNASDAQ
🏆 #4823 by market capUS Equity
$208.01▲ $9.98 (+4.80%)
Simulated price
🔔
Track PTN
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$17M
Small Cap
📈Revenue Growth (YoY)
+3581.2%
High Growth
📊Gross Margin
97.8%
High
💵FCF Margin
29.6%
Strong
⚖️P/S Ratio
1.3x
Cheap
Otter Score
80
Good
No chart data available for PTN.

Trading Snapshot

Day Range
$206.63 – $209.72
52-Week Range
$5.61 – $31.00
Volume
$3.63B
Avg Volume
$4.54B
Shares Outstanding
1.8M
Next Earnings
Nov 11, 2026

Fundamentals Snapshot

Annual Revenue
$13M
Last Q Revenue
$3M
P/E Ratio
—
P/S Ratio
1.3x
EPS (TTM)
$-1.69
Dividend Yield
—
Dilution (1yr)
−85.6%

Why Investors Own PTN

  • ✓High-growth profile — revenue up +40.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 71% gross margin and 23% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PTN logo

PALATIN TECHNOLOGIES INC

PTN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.8%▲ +7.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$17M▼ −22.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$21M▼ −32.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.1M▼ −85.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$14M▲ +$11M YoY
StockOtter · stockotter.space

About PALATIN TECHNOLOGIES INC

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$272.99
▲ +31.2% Upside
High Target$295.39
Low Target$253.18
Based on 38 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

PALATIN TECHNOLOGIES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift PTN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

PALATIN TECHNOLOGIES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.